VRTX officer sells 1,953 shares under 10b5-1 plan

Q: What did Jonathan Biller (VRTX) report on this Form 4?

He reported dispositions of 1,259 shares at $400 on 10/01/2025 and 694 shares at $404.21 on 10/02/2025 .

Q: Who signed the Form 4 for these transactions?

The Form 4 is signed by Christiana Stevenson, Attorney-in-Fact , on 10/03/2025 .

Q: What were the execution dates of the reported VRTX trades?

The trades were executed on 10/01/2025 and 10/02/2025 , per the form.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), reported insider dispositions under a company-approved Rule 10b5-1 trading plan entered on 02/24/2025. On 10/01/2025 he disposed of 1,259 shares at $400, reducing his beneficial ownership to 16,347 shares, and on 10/02/2025 he sold 694 shares at $404.21, leaving 15,653 shares beneficially owned after the second transaction. The filing is signed by an attorney-in-fact on 10/03/2025.

Positive

Trades executed under a company-approved Rule 10b5-1 plan entered on 02/24/2025

Negative

Total dispositions of 1,953 shares (1,259 at $400 and 694 at $404.21)
Beneficial ownership decreased to 15,653 shares following the reported transactions

Insights

Insider sales executed under an approved 10b5-1 plan; total disposition 1,953 shares across two dates.

These sales were executed under a pre-established Rule 10b5-1 plan entered 02/24/2025, which the filing explicitly cites as the transaction authority. That indicates the trades were scheduled under an approved plan rather than opportunistic ad-hoc trades.

The filing shows discrete disposals of 1,259 shares at $400 on 10/01/2025 and 694 shares at $404.21 on 10/02/2025, leaving 15,653 shares after the latter sale. The form is signed by an attorney-in-fact on 10/03/2025.

Insider Trade Summary

Net Seller: 1,953 shares

Net Sell 2 txns

Insider Biller Jonathan

Role EVP and Chief Legal Officer

Sold 694 shs ($281K)

Type	Security	Shares	Price	Value
Sale	Common Stock	694	$404.21	$281K
Exercise Price or Tax Liability	Common Stock	1,259	$400.00	$504K

Holdings After Transaction: Common Stock — 15,653 shares (Direct)

Footnotes (1)

F1. Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/03/2025 - 04:07 PM

FAQ

What did Jonathan Biller (VRTX) report on this Form 4?

He reported dispositions of 1,259 shares at $400 on 10/01/2025 and 694 shares at $404.21 on 10/02/2025.

Were the trades part of a trading plan for VRTX insiders?

Yes. The filing states the transactions were made pursuant to a company-approved Rule 10b5-1 trading plan entered on 02/24/2025.

How many VRTX shares did Biller beneficially own after these transactions?

After the reported sales, the filing shows he beneficially owned 15,653 shares.

Who signed the Form 4 for these transactions?

The Form 4 is signed by Christiana Stevenson, Attorney-in-Fact, on 10/03/2025.

What were the execution dates of the reported VRTX trades?

The trades were executed on 10/01/2025 and 10/02/2025, per the form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Biller Jonathan

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2025		F		1,259	D	$400	16,347	D
Common Stock	10/02/2025		S⁽¹⁾		694	D	$404.21	15,653	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR